Comparing SG&A Expenses: Lantheus Holdings, Inc. vs Soleno Therapeutics, Inc. Trends and Insights

SG&A Expenses: Lantheus vs. Soleno - A Decade of Growth

__timestampLantheus Holdings, Inc.Soleno Therapeutics, Inc.
Wednesday, January 1, 2014724290002917513
Thursday, January 1, 2015786340007878291
Friday, January 1, 2016753740008366794
Sunday, January 1, 2017921570006610381
Monday, January 1, 2018933260006556000
Tuesday, January 1, 20191031320006930000
Wednesday, January 1, 20201101710008758000
Friday, January 1, 202121881700010806000
Saturday, January 1, 20222338270009844000
Sunday, January 1, 202326719400013481000
Loading chart...

Unleashing insights

SG&A Expenses: A Tale of Two Companies

Lantheus Holdings, Inc. vs. Soleno Therapeutics, Inc.

In the ever-evolving landscape of the healthcare sector, understanding the financial dynamics of companies is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Lantheus Holdings, Inc. and Soleno Therapeutics, Inc. from 2014 to 2023.

Lantheus Holdings has shown a remarkable upward trend, with SG&A expenses increasing by approximately 270% over the decade. This growth reflects their expanding operations and strategic investments. In contrast, Soleno Therapeutics, while maintaining a steady trajectory, has seen a more modest increase of around 360% in the same period, indicating a more conservative approach to scaling their operations.

The data highlights the contrasting strategies of these two companies, offering insights into their financial health and operational priorities. As the healthcare industry continues to grow, these trends provide a window into the future strategies of these key players.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025